Skip to main content


Audience for the document: Share Class: Language of the document:


Share Class: Language of the document:

Change Details

If you need to change your email address please contact us.
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the twenty four-year period ended June 30, 2020, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest

Please enter valid search characters

December 2020 / MARKETS & ECONOMY

Market Optimism May Be Justified—But I Urge Caution

Weak growth and a fiscally hamstrung U.S. signal trouble ahead

While the U.S. elections grind toward the finish line, risk markets—after a bumpy ride—are hovering close to all‑time highs. In light of surprisingly close elections that will likely lead to a split Congress, legislative gridlock, and inadequate fiscal support, this may seem surprising. The surprise grows when one considers the coronavirus wave that is breaking across Europe and the U.S., leaving a swath of lockdowns in its wake. How did the markets get here? Where do we go next? 

The U.S. elections are likely to lead to a Democratic president accompanied by a Democratic House and a Republican Senate—and based on previous experience of divided governments over the past decade, we should expect very little legislative progress during the term of President‑elect Joe Biden. The good news for risk investors is that Biden’s planned corporate tax increases are unlikely to come to fruition; the not‑so‑good news is that coronavirus‑related stimulus is likely to be significantly smaller and the tax‑financed infrastructure package has been canceled altogether. 

Looming Lockdowns and Positive Sentiment Make an Odd Combination 

The markets decided to take their cue from the good news about tax increases—well, that and the assumption that we are in the early stage of the next business cycle expansion (a view that was reinforced when Pfizer, a couple of days later, announced that its prospective coronavirus vaccine delivers an immunity effectiveness of 94%). Consequently, risk markets staged a spectacular rally. 

...investors seem willing to look past the data volatility....

As things stand, investors seem willing to look past the data volatility and sweeping lockdowns that have arisen on the back of the second coronavirus outbreak. Whether they are right to do so remains to be seen, but for now—the argument runs—the policy response is already in place, and the second wave outbreak is unlikely to lead to a run on the financial system akin to what we experienced earlier in the year. Furthermore, given developments on the vaccine front, the current outbreak will likely be the swan song of the coronavirus. Good riddance. 

I am skeptical of the view that lockdowns will be short-lived....

While these arguments make sense, the combination of a second coronavirus outbreak and market optimism gives me reason to pause. Economists have substantially reduced their growth expectations for the eurozone for the fourth quarter of 2020, and I harbor no optimism that the U.S. will fare any better as the authorities there continue to express overly optimistic views that leave no doubt that they are far behind the virus curve. I am skeptical of the view that lockdowns will be short‑lived and followed by sharp rebounds: It is a very different proposition to remove lockdowns during peak flu season than during warm‑weather months. Moreover, in the absence of a strong fiscal response, it is not clear to me that household balance sheets will weather mobility restrictions as well as they did during the previous lockdown. 

Biden’s Likely Inability to Raise Taxes Is Not a Net Positive 

I believe that the combination of a rapid growth deceleration, monetary policies that are running on empty, a backloaded and timid U.S. fiscal response, and companies that have been struggling for a year to keep their heads above water warrants some caution—which is not what the markets have exhibited since the U.S. elections. As an economist, I am more concerned about what I believe to be the failing fiscal agenda in the U.S. than I am encouraged by the fact that Biden is unlikely to be able to raise taxes. The inability to raise the corporate tax rate is not a windfall gain for the economy as the lack of tax revenues is offset in more than unit measure in near‑term fiscal spending. Net, this is not positive for growth. Most likely, everything will be fine, but the risk of a double‑dip recession has undoubtedly increased over the past month. 

On the other hand, the likely change at the helm of the White House should lead to a more orthodox and predictable foreign policy. The frictions between China and the U.S. are unlikely to wither under Biden, but soon the trade war should be reduced to a small dot in the rearview mirror—undoubtedly a positive development. 

Encouragingly, the third‑largest economy, China, seems to keep ticking along. The country’s recovery from the virus‑induced growth slowdown and ability to manage subsequent virus outbreaks has been nothing but spectacular. Consequently, while the authorities in China are unlikely to pull the rug from under the economy, they are clearly steering it away from the government support measures—a development that has yet to show up in the data but that, in my view, is likely to appear over the coming quarters.  

Altogether, while the passage of the U.S. elections has prompted investors to shift attention to the business cycle expansion, immense challenges loom over the next few quarters. Preserving some dry investment powder may be a wise decision. 



This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.

Previous Article


Central Banks Are Not Out of Ammunition Yet
Next Article

December 2020 / MARKETS & ECONOMY

Innovation Drives Health Care Sector’s Response to Pandemic

You are now leaving the T. Rowe Price website

T. Rowe Price is not responsible for the content of third party websites, including any performance data contained within them. Past performance cannot guarantee future results.